X0306 4 2018-07-20 0 0001658247 Crinetics Pharmaceuticals, Inc. CRNX 0001589315 5AM Ventures IV, L.P. 501 2ND STREET, SUITE 350 SAN FRANCISCO CA 94107 0 0 1 0 0001593361 5AM Co-Investors IV, L.P. 501 2ND STREET, SUITE 350 SAN FRANCISCO CA 94107 0 0 1 0 0001589314 5AM Partners IV, LLC 501 2ND STREET, SUITE 350 SAN FRANCISCO CA 94107 0 0 1 0 0001219014 ROCKLAGE SCOTT M 501 2ND STREET, SUITE 350 SAN FRANCISCO CA 94107 0 0 1 0 0001240357 DIEKMAN JOHN D 501 2ND STREET, SUITE 350 SAN FRANCISCO CA 94107 0 0 1 0 0001598549 Schwab Andrew J. 501 2ND STREET, SUITE 350 SAN FRANCISCO CA 94107 0 0 1 0 Common Stock 2018-07-20 4 C 0 2797635 A 2797635 I See footnotes Common Stock 2018-07-20 4 C 0 451274 A 3248909 I See footnotes Common Stock 2018-07-20 4 C 0 116567 A 116567 I See footnotes Common Stock 2018-07-20 4 C 0 18802 A 135369 I See footnotes Common Stock 2018-07-20 4 P 0 110400 17 A 3359309 I See footnotes Common Stock 2018-07-20 4 P 0 4600 17 A 139969 I See footnotes Series A Preferred Stock 2018-07-20 4 C 0 9204220 D Common Stock 2797635 0 I See footnotes Series B Preferred Stock 2018-07-20 4 C 0 1484690 D Common Stock 451274 0 I See footnotes Series A Preferred Stock 2018-07-20 4 C 0 383507 D Common Stock 116567 0 I See footnotes Series B Preferred Stock 2018-07-20 4 C 0 61861 D Common Stock 18802 0 I See footnotes These securities are held of record by 5AM Ventures IV, L.P. ("Ventures IV"). Following the transactions reported herein, 3,359,309 shares of Common Stock are held of record by Ventures IV. These securities are held of record by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Following the transactions reported herein, 139,969 shares of Common Stock are held of record by Co-Investors IV. 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein. Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date. 5AM VENTURES IV, L.P. By: 5AM Partners IV, LLC, its General Partner /s/ Scott M. Rocklage Managing Member 2018-07-20 5AM CO-INVESTORS IV, L.P. By: 5AM Partners IV, LLC, its General Partner /s/ Scott M. Rocklage Managing Member 2018-07-20 5AM PARTNERS IV, LLC /s/ Scott M. Rocklage Managing Member 2018-07-20 /s/ Scott M. Rocklage 2018-07-20 /s/ John D. Diekman 2018-07-20 /s/ Andrew J. Schwab 2018-07-20